| Objective: The mechanism of Kangmai Ⅱ capsule treating deep vein thrombosis of lower extremity through TXB2/6-Keto-PGF1α pathway was verified by animal experiments.Methods: The rats were treated with Kangmai Ⅱ capsule suspension by gavage.The rats in the control group were treated with Mailuo-Shutong pill suspension by gavage.The changes of the symptoms and signs of the rats were observed.Results: 1.On the first day after modeling,the rats gradually showed symptoms of lower limb redness and swelling,increased skin temperature,limited activity,significantly reduced activity,reduced food intake and water intake,etc.Rats in group C(Mailuoshuotong pill control group)and group D(Kangmai Ⅱ capsule treatment group)were given medicine on the 2nd day after modeling,and symptoms of rats were gradually alleviated with the increase of time during the 1st to 14 th day after administration2.On the second day after modeling,the plasma content of TXB2 in group A(sham operation group)was lower than that in group B(Control group of thrombus model),group C(Mailuoshutong pill control group)and group D(Kangmai Ⅱ capsule treatment group).The plasma content of 6-Keto-PGF1α in group A(sham operation group)was higher than that in group B((Control group of thrombus model),group C(Mailuoshuotong pill control group)and group D(Kangmai Ⅱ capsule treatment group).3.On the 8th and 15 th day after modeling,the plasma TXB2 content of rats in Group C(Mailuoshutong pill control group)and Group D(Kangmai Ⅱ capsule treatment group)was significantly decreased after treatment,and the plasma TXB2 content of rats in Group C(Mailuoshutong pill control group)and Group D(Kangmai Ⅱ capsule treatment group)was lower than that in Group B((Control group of thrombus model)after treatment,with significant difference(P < 0.05).The plasma content of 6-Keto-PGF1α in each group was measured after treatment.The content of 6-Keto-PGF1α in plasma of rats in group C(Mailuoshuotong pill control group)and group D(Kangmai Ⅱ capsule treatment group)was significantly increased,and the content of 6-Keto-PGF1α in plasma of rats in group C(Mailuoshuotong pill control group)and group D(Kangmai Ⅱ capsule treatment group)was higher than that in group B(Control group of thrombus model)after treatment,with significant difference(P < 0.05).4.On the 8th and 15 th day after modeling,blood samples of the four groups of rats were collected,and TXB2/6-Keto-PGF1α in plasma of each group were measured after medication.TXB2/6-Keto-PGF1α in group C(Mailuoshutong pill control group)and group D(Kangmai Ⅱ capsule treatment group)were significantly decreased.TXB2/6-Keto-PGF1α in group C(Mailuoshuotong pill control group)and group D(Kangmai Ⅱ capsule treatment group)was significantly lower than that in group B(model control group)(P < 0.05).Conclusion: 1.Kangmai Ⅱ capsule can decrease the content of TXB2 and increase the content of 6-Keto-PGF1α in plasma of rats with deep vein thrombosis in lower limbs.2.One of the mechanisms of Kangmai Ⅱ in the treatment of lower extremity deep vein thrombosis is to effectively improve the imbalance of TXB2/6-Keto-PGF1α.In the treatment of lower extremity deep vein thrombosis,6-Keto-PGF1α mainly plays its role of inhibiting platelet adhesion and aggregation. |
PDF Full Text Request